What happens when an AI-based symptom checker & an online self-referral tool play Rheumatologists? They don't seem to do great yet! 600 new pts, outw/ 36% dvlpd IA IA Sens 62% Spe 47% Tool Sens 66% Spe 54% More work needed to implement these in practice #EULAR23 @Rheumnow

RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

RheumNow Eular 2023 Daily Recap Series https://t.co/ZJd3mSBcau

• https://twitter.com/i/broadcasts/1djxXlQmVZyxZ

AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/PPI1fvwLAf https://t.co/qMXMsbpwl3

• https://bit.ly/3ONeMdz

Top Influencers of #EULAR2023 👉 @eular_org @EMEUNET @RheumNow @ARD_BMJ @drdavidliew @Janetbirdope https://t.co/uUJM6tW824 via @symplur

• #EULAR2023 - eular 23 - Social Media Analytics and Transcripts

Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco. Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz

#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P

Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on YouTube, Twitter and LinkedIn. https://t.co/i8rm5t8mFS

RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA

Adherence to TNFi follows different trajectories Cluster 1: “moderate then high” 51% Cluster 2: “moderate then low” 20% Cluster 3: “low adherence, to discontinuation” 18% Cluster 4: “low then high adherence” 11% Most demographic & clinical features CAN NOT predict trajectory! https://t.co/4wLg6b70Kl